Preparation, Standardization and Anti-plasmodial Efficacy of Novel Malaria NosodesFunding The work was funded by the Central Council for Research in Homoeopathy (CCRH), Ministry of AYUSH, Government of India, New Delhi, under the project number 42/2016/17.
Background Resistance to artemisinin and its partner drugs has threatened the sustainability of continuing the global efforts to curb malaria, which urges the need to look for newer therapies to control the disease without any adverse side effects. In the present study, novel homeopathic nosodes were prepared from Plasmodium falciparum and also assessed for their in vitro and in vivo anti-plasmodial activity.
Methods Three nosodes were prepared from P. falciparum (chloroquine [CQ]-sensitive [3D7] and CQ-resistant [RKL-9] strains) as per the Homeopathic Pharmacopoeia of India, viz. cell-free parasite nosode, infected RBCs nosode, mixture nosode. In vitro anti-malarial activity was assessed by schizont maturation inhibition assay. The in vitro cytotoxicity was evaluated by MTT assay. Knight and Peter's method was used to determine in vivo suppressive activity. Mice were inoculated with P. berghei-infected erythrocytes on day 1 and treatment was initiated on the same day. Biochemical, cytokine and histopathological analyses were carried out using standard methods.
Results In vitro: the nosodes exhibited considerable activity against P. falciparum with maximum 71.42% (3D7) and 68.57% (RKL-9) inhibition by mixture nosode followed by cell-free parasite nosode (62.85% 3D7 and 60% RKL-9) and infected RBCs nosode (60.61% 3D7 and 57.14% RKL-9). The nosodes were non-toxic to RAW macrophage cell line with >70% cell viability. In vivo: Considerable suppressive efficacy was observed in mixture nosode-treated mice, with 0.005 ± 0.001% parasitemia on day 35. Levels of liver and kidney function biomarkers were within the normal range in the mixture nosode-treated groups. Cytokine analysis revealed increased levels of IL-4 and IL-10, whilst a decline in IL-17 and IFN-γ was evident in the mixture nosode-treated mice.
Conclusion The mixture nosode exhibited promising anti-malarial activity against P. falciparum and P. berghei. Biochemical and histopathological studies also highlighted the safety of the nosode for the rodent host. The study provides valuable insight into a novel medicament that has potential for use in the treatment of malaria.
† Professor Upma Bagai died on September 8th, 2018.
Eingereicht: 05. November 2020
Angenommen: 25. Februar 2021
Artikel online veröffentlicht:
12. November 2021
© 2021. Faculty of Homeopathy. This article is published by Thieme.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 World Health Organization (WHO). World Malaria Report 2020. Geneva: WHO; ; November 30, 2020
- 2 Centers for Disease Control and Prevention. 2016 Malaria: Biology. Accessed on October 21, 2020 at: https://www.cdc.gov/Malaria/about/biology/index.html
- 3 Marsh K. Malaria disaster in Africa. Lancet 1998; 352: 924-925
- 4 Vangapandu S, Jain M, Kaur K, Patil P, Patel SR, Jain R. Recent advances in antimalarial drug development. Med Res Rev 2007; 27: 65-107
- 5 Bagai U, Rajan A, Kaur S. Antimalarial potential of Nosode 30 and 200 against Plasmodium berghei infection in BALB/c mice. J Vector Borne Dis 2012; 49: 72-77
- 6 Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 1976; 193: 673-675
- 7 World Health Organization. In vitro Micro Test (mark III) for the Assessment of Response of Plasmodium falciparum to chloroquine, Mefloquine, Quinine, Amodiaquine, Sulfadoxine, Pyrimethamine and Artemisinin. CTD/MAL/97, 20. Geneva: World Health Organization; 2001
- 8 Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63
- 9 Knight DJ, Peters W. The antimalarial activity of N-benzyloxydihydrotriazines. I. The activity of clociguanil (BRL 50216) against rodent malaria, and studies on its mode of action. Ann Trop Med Parasitol 1980; 74: 393-404
- 10 Peters W. Drug resistance in Plasmodium berghei Vincke and Lips, 1948. I. Chloroquine resistance. Exp Parasitol 1965; 17: 80-89
- 11 Baker JR. Histochemical analysis. In: Abercrombie M. ed. Cytological technique. 2nd ed.. London: Metheren and Co. Pub; 1946: 155-162
- 12 Patel B, Mashru R. Viral nosodes as an alternative to vaccination: An update. J Immunol Vaccine Technol 2017; 2: 106
- 13 Allen TF. The Encyclopedia of Pure Materia Medica. Vol. 8.. New Delhi: B. Jain Publishers; 1988: 164
- 14 Sinha S, Sarma P, Sehgal R, Medhi B. Development in assay methods for in vitro antimalarial drug efficacy testing: a systematic review. Front Pharmacol 2017; 8: 754
- 15 Wang J, Hernandez L, Kodali S, Cully D, Singh S. A target-specific whole cell assay for antibacterial drug discovery. Protoc Exch , June 23, 2006; DOI: 10.1038/nprot.2006.130. https://protocolexchange.researchsquare.com/article/nprot-7/v1
- 16 Hobbs C, Duffy P. Drugs for malaria: something old, something new, something borrowed. F1000 Biol Rep 2011; 3: 24
- 17 Lekana-Douki JB, Bongui JB, Oyegue Liabagui SL. et al. In vitro antiplasmodial activity and cytotoxicity of nine plants traditionally used in Gabon. J Ethnopharmacol 2011; 133: 1103-1108
- 18 Rajan A, Bagai U. Antimalarial potential of homeopathic medicines against schizont maturation of Plasmodium berghei in short-term in vitro culture. Int J High Dilution Res 2012; 11: 224-236
- 19 Tasanor O, Noedl H, Na-Bangchang K, Congpuong K, Sirichaisinthop J, Wernsdorfer WH. An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine. Acta Trop 2002; 83: 49-61
- 20 Khuda-Bukhsh AR, Mondal J, Shah R. Therapeutic potential of HIV nosode 30c as evaluated in A549 lung cancer cells. Homeopathy 2017; 106: 203-213
- 21 Mondal J, Das J, Shah R, Khuda-Bukhsh AR. A homeopathic nosode, Hepatitis C 30 demonstrates anticancer effect against liver cancer cells in vitro by modulating telomerase and topoisomerase II activities as also by promoting apoptosis via intrinsic mitochondrial pathway. J Integr Med 2016; 14: 209-218
- 22 Gorki V, Walter NS, Singh R. et al. β-carboline derivatives tackling malaria: Biological evaluation and docking analysis. ACS Omega 2020; 5: 17993-18006
- 23 Gorki V, Singh R, Walter NS, Bagai U, Salunke DB. Synthesis and evaluation of antiplasmodial efficacy of β-carboline derivatives against murine malaria. ACS Omega 2018; 3: 13200-13210
- 24 Oyewole I, Senusie S, Mansaray M. Plasmodium falciparum-induced kidney and liver dysfunction in malaria patients in Freetown, Sierra Leone. Sierra Leone J Biomed Res 2010; 2: 70-74
- 25 Onyesom I, Onyemakonor N. Levels of parasitaemia and changes in some liver enzymes among malarial infected patients in Edo-Delta region of Nigeria. Curr Res J Biol Sci 2011; 3: 78-81
- 26 Ignatius CM, Emeka EN, Blessing NE. Effect of malaria parasitaemia on liver enzyme tests. Int J Trop Med 2008; 3: 49-52
- 27 Prakash J, Singh AK, Gujrati S, Maheshwan A. Acute renal failure in malaria: changing trends. Indian J Nephrol 2002; 12: 113-117
- 28 World Health Organization. WHO Guidelines for the Treatment of Malaria. 2nd ed.. 2010
- 29 Akanbi OM. The influence of malaria infection on kidney and liver function in children in Akoko area of Ondo state, Nigeria. J Parasitol Vector Biol 2015; 7: 163-168
- 30 Pathak VA, Ghosh K. Erythropoiesis in malaria infections and factors modifying the erythropoietic response. Anemia 2016; 2016: 9310905
- 31 Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765
- 32 Rajan A, Bagai U. Evaluation of antiplasmodial efficacy and safety of Cinchona officinalis against lethal murine malaria parasite. AJHM 2012; 105: 76-83